Skip to content

Investigation to Evaluate Performance and Safety of RemovAid ™ in Removal of Contraceptive Implants

A Prospective, Single-centre, Non-comparative Feasibility Investigation to Evaluate Performance and Safety of RemovAid ™ Retrieval Device When Used for Removal of Palpable Subdermal Contraceptive Rod Implants

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03912649
Acronym
REVALID03
Enrollment
15
Registered
2019-04-11
Start date
2019-06-11
Completion date
2020-11-18
Last updated
2021-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Removal Contraceptive Implant

Brief summary

The safety and efficacy of a subdermal implant retrieval device (RemovAid) is investigated in a population of 25 women seeking removal of their palpable contraceptive implants. The primary endpoint of the device is to evaluate the performance of the device, specifically its success rate in removing palpable contraceptive implants. The device shall be able to fixate at least 80% of palpable implants, and successfully remove at least 90% of these implants.

Detailed description

Similar to the REVALID and REVALID02 investigations, the REVALID03 investigation aims to recruit a total of 25 women with a palpable contraceptive implant due for removal, in order to obtain at least 20 successful fixations. The implant retrieval device aims to standardize and simplify the implant removal procedure. There is no comparator in the investigation. Descriptive data will be recorded, all recruited subjects will be exposed to the investigational medical device (IMD) The primary endpoint is the percentage of fixated implants that are successfully removed without the use of additional tools.

Interventions

DEVICERemovAid

The RemovAid device is used for removal

Sponsors

Karolinska University Hospital
CollaboratorOTHER
RemovAid AS
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Female age 18 or older * Willing to remove a palpable subdermal Implanon/ Nexplanon CI * Willing and able to give written informed consent for participation in the investigation * Willing to provide follow-up information according to the Clinical Investigators brochure

Exclusion criteria

* Known allergy to local anaesthetic (lidocaine/lignocaine) or disinfectant (chlorhexidine). * Active skin lesion over the CI. * The Investigator considers the subject unlikely to comply with investigational procedures, restrictions and requirements. * Any contraindication for removal of the PI, as judged by the Investigator. * Any disorders or medications that might affect coagulation, as judged by the Investigator. * Any conditions suspected to affect healing or increase risk of infection (e.g. keloid tendency, diabetes or any upper arm dermatological condition that may affect upper arm healing)

Design outcomes

Primary

MeasureTime frameDescription
Successful removal of implant15 minutesThe percentage of fixated implants that are successfully removed by the device without the use of additional tools

Secondary

MeasureTime frameDescription
Pain during procedure: Visual Analogue Scale15 minutesMean pain score (maximum pain intensity during the procedure) indicated by the subject on a Visual Analogue Scale 0-100 mm ruler, assuming that anaesthesia has been properly administered. Higher values represent a worse outcome.
Success of fixation of implant5 minutesPercentage of palpable implants where the implant could be seen and/or felt on both sides of the clamp after maximum three attempts of fixation. 80% or more is considered success.
Duration of procedure25 minutesMean time from making incision until implant is removed, and first touching subject with the device until implant extracted
Frequency, severity, causality and outcome of adverse events (AEs)1 weekBoth Anticipated and unanticipated AEs will be recorded, both immediately following the intervention and at follow-up
Operators impression of the device5 minutesThe operator's global impression of the IMD will be assessed using a scale 1-5, where 5 is excellent and 1= poor
Subject satisfaction: 5- point scale5 minutesThe subject's global assessment of satisfaction with the procedure will be assessed using a scale of 1-5, where 5 is excellent
Technical functionality of device determined by an operators questionnaire5 minutesFulfilment of pre-defined technical requirements, as documented on an operator functionality questionnaire. The questionnaire consists of a range of yes/no questions to device functionality

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026